Randomization and placebo groups are giving way to biomarkers, real-world data from wearables, and multi-center and adaptive trials.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Living with adrenoleukodystrophy: adult patient and caregiver perspectives
Orphanet Journal of Rare Diseases Open Access 08 January 2026
-
Retrospective assessment of clinical global impression of severity and change in GM1 gangliosidosis: a tool to score natural history data in rare disease cohorts
Orphanet Journal of Rare Diseases Open Access 14 March 2025
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
May, M. Rare-disease researchers pioneer a unique approach to clinical trials. Nat Med 29, 1884–1886 (2023). https://doi.org/10.1038/s41591-023-02333-4
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-023-02333-4
This article is cited by
-
Living with adrenoleukodystrophy: adult patient and caregiver perspectives
Orphanet Journal of Rare Diseases (2026)
-
Retrospective assessment of clinical global impression of severity and change in GM1 gangliosidosis: a tool to score natural history data in rare disease cohorts
Orphanet Journal of Rare Diseases (2025)
-
Insights into Support Systems for Orphan Drug Development: A Comparative Study
Therapeutic Innovation & Regulatory Science (2025)
-
tRNA therapeutics for genetic diseases
Nature Reviews Drug Discovery (2024)